AT2220 Co-Administered with EnzymeA protein that helps the body carry out chemical reactions. More Replacement Therapy
Second Phase 2 Pharmacological Chaperone-ERT Co-Administration Study
CRANBURY, NJ, US, December 1, 2011 – Amicus Therapeutics, a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced the initial infusionA method of delivering medication through an IV. More of the first subject in an open-label Phase 2 drug-drug interaction study (Study 010) of AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT)A treatment that replaces the missing enzyme through IV infusion. More in individuals with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More.
The purpose of Study 010 is to evaluate whether AT2220, an orally available, investigational pharmacological chaperone owned exclusively by Amicus, can be safely co-administered with the ERT alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More, the only approved therapy for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More. All subjects will be given a regularly scheduled ERT infusionA method of delivering medication through an IV. More. One hour prior to the initiation of the next ERT infusionA method of delivering medication through an IV. More, subjects will receive a single oral dose of AT2220. In Study 010, alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More will be measured in plasma and muscle tissue, with and without AT2220.
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics said, “ERT is an important first generation treatment that has extended the lives of many individuals living with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More. We believe that chaperone-ERT co-administration has the potential to improve treatment outcomes for Pompe patients, and we are excited about commencing Study 010. Along with our work in Fabry, the co-administration approach may represent an important expansion of our technology platform into other lysosomal storage diseasesA group of diseases in which substances build up inside lysosomes because the body cannot break them... More where ERT is standard of care.”
In acid alpha-glucosidase (GAA)The enzyme the body needs to break down glycogen. In Pompe disease, this enzyme is missing or does n... More knock-out mouse modelsA laboratory mouse used to study disease and test treatments before human trials. More of Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More, AT2220 co- administered with ERT increased ERT activity in plasma and uptake into key tissues, which corresponded with greater reductions in muscle glycogenA stored form of sugar used for energy. More, compared to ERT alone. Collectively these preclinical data highlight the potential for AT2220 to improve ERT in patients with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More.
“Results from Study 010, if positive, may form the basis for later stage studies that would allow us to evaluate the effect of AT2220 co-administered with ERT on glycogenA stored form of sugar used for energy. More reduction and ERT- related toxicity in patients with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More,” said Pol F. Boudes, Chief Medical Officer of Amicus.
Study Design
Study 010 is a Phase 2 open-label, multi-center study to evaluate the safety and pharmacokinetic (PK) effects of four increasing oral doses of AT2220 co-administered with ERT versus ERT alone in individuals with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More.
The study will enroll approximately 16 male or female subjects who have been on a stable dose and regimen of ERT for at least three months. All subjects will be given a regularly scheduled ERT infusionA method of delivering medication through an IV. More. One hour prior to the initiation of the next ERT infusionA method of delivering medication through an IV. More, subjects will receive a single oral dose of AT2220. Plasma enzymeA protein that helps the body carry out chemical reactions. More activity and protein levels will be evaluated during each infusionA method of delivering medication through an IV. More. Muscle biopsies will be taken seven days after each infusionA method of delivering medication through an IV. More to measure tissue ERT activity with and without the chaperone, as well as the level of AT2220.
More information about Study 010, including patient eligibility, enrollment requirements and study location sites can be obtained by visiting www.clinicaltrials.gov: NCT1380743 or www.pompestudy.com, calling the patient hotline at 855-POMPE-33 (855-766-7333), or e- mailing inquiries to info@pompestudy.com.